PRMT5-mediated methylation of MST2 inhibits the Hippo signaling pathway, promoting PDAC progression and metastasis, while PRMT5 inhibition restores Hippo pathway activity and suppresses tumor growth [90]. The gene discussed is PRMT5; the disease is neoplasm.